Global Therapeutic Nuclear Medicines Market Overview And Scope:
Global Therapeutic Nuclear Medicines Market Size was estimated at USD 1672.91 million in 2022 and is projected to reach USD 4557.6 million by 2028, exhibiting a CAGR of 18.18% during the forecast period.
The Global Therapeutic Nuclear Medicines Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Therapeutic Nuclear Medicines utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Novartis AG, Bayer, China Isotope and Radiation, Q BioMed, Curium Pharmaceuticals, Jubilant DraxImage, Dongcheng, Lantheus, Acrotech Biopharma., Progenics Pharmaceuticals, International Isotopes
Global Therapeutic Nuclear Medicines Market Segmentation
By Type, Therapeutic Nuclear Medicines market has been segmented into:Radium-223
Lutetium-177
Iodine-131
Other
By Application, Therapeutic Nuclear Medicines market has been segmented into:
Thyroid
Bone Metastasis
Lymphoma
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Therapeutic Nuclear Medicines market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Therapeutic Nuclear Medicines market.
Top Key Players Covered in Therapeutic Nuclear Medicines market are:
Novartis AG
Bayer
China Isotope and Radiation
Q BioMed
Curium Pharmaceuticals
Jubilant DraxImage
Dongcheng
Lantheus
Acrotech Biopharma.
Progenics Pharmaceuticals
International Isotopes
Objective to buy this Report:
1. Therapeutic Nuclear Medicines analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Therapeutic Nuclear Medicines market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Therapeutic Nuclear Medicines Market by Type
5.1 Therapeutic Nuclear Medicines Market Overview Snapshot and Growth Engine
5.2 Therapeutic Nuclear Medicines Market Overview
5.3 Radium-223
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Radium-223: Geographic Segmentation
5.4 Lutetium-177
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Lutetium-177: Geographic Segmentation
5.5 Iodine-131
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Iodine-131: Geographic Segmentation
5.6 Other
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Other: Geographic Segmentation
Chapter 6: Therapeutic Nuclear Medicines Market by Application
6.1 Therapeutic Nuclear Medicines Market Overview Snapshot and Growth Engine
6.2 Therapeutic Nuclear Medicines Market Overview
6.3 Thyroid
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Thyroid: Geographic Segmentation
6.4 Bone Metastasis
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Bone Metastasis: Geographic Segmentation
6.5 Lymphoma
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Lymphoma: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Therapeutic Nuclear Medicines Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Therapeutic Nuclear Medicines Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Therapeutic Nuclear Medicines Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 NOVARTIS AG
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 BAYER
7.4 CHINA ISOTOPE AND RADIATION
7.5 Q BIOMED
7.6 CURIUM PHARMACEUTICALS
7.7 JUBILANT DRAXIMAGE
7.8 DONGCHENG
7.9 LANTHEUS
7.10 ACROTECH BIOPHARMA.
7.11 PROGENICS PHARMACEUTICALS
7.12 INTERNATIONAL ISOTOPES
Chapter 8: Global Therapeutic Nuclear Medicines Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Radium-223
8.2.2 Lutetium-177
8.2.3 Iodine-131
8.2.4 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Thyroid
8.3.2 Bone Metastasis
8.3.3 Lymphoma
8.3.4 Other
Chapter 9: North America Therapeutic Nuclear Medicines Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Radium-223
9.4.2 Lutetium-177
9.4.3 Iodine-131
9.4.4 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Thyroid
9.5.2 Bone Metastasis
9.5.3 Lymphoma
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Therapeutic Nuclear Medicines Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Radium-223
10.4.2 Lutetium-177
10.4.3 Iodine-131
10.4.4 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Thyroid
10.5.2 Bone Metastasis
10.5.3 Lymphoma
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Therapeutic Nuclear Medicines Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Radium-223
11.4.2 Lutetium-177
11.4.3 Iodine-131
11.4.4 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Thyroid
11.5.2 Bone Metastasis
11.5.3 Lymphoma
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Therapeutic Nuclear Medicines Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Radium-223
12.4.2 Lutetium-177
12.4.3 Iodine-131
12.4.4 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Thyroid
12.5.2 Bone Metastasis
12.5.3 Lymphoma
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Therapeutic Nuclear Medicines Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Radium-223
13.4.2 Lutetium-177
13.4.3 Iodine-131
13.4.4 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Thyroid
13.5.2 Bone Metastasis
13.5.3 Lymphoma
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Therapeutic Nuclear Medicines Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Radium-223
14.4.2 Lutetium-177
14.4.3 Iodine-131
14.4.4 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Thyroid
14.5.2 Bone Metastasis
14.5.3 Lymphoma
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Therapeutic Nuclear Medicines Scope:
|
Report Data
|
Therapeutic Nuclear Medicines Market
|
|
Therapeutic Nuclear Medicines Market Size in 2025
|
USD XX million
|
|
Therapeutic Nuclear Medicines CAGR 2025 - 2032
|
XX%
|
|
Therapeutic Nuclear Medicines Base Year
|
2024
|
|
Therapeutic Nuclear Medicines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Novartis AG, Bayer, China Isotope and Radiation, Q BioMed, Curium Pharmaceuticals, Jubilant DraxImage, Dongcheng, Lantheus, Acrotech Biopharma., Progenics Pharmaceuticals, International Isotopes.
|
|
Key Segments
|
By Type
Radium-223
Lutetium-177
Iodine-131
Other
By Applications
Thyroid
Bone Metastasis
Lymphoma
Other
|
